Trial Profile
A Single Ascending Dose (SAD)/Multiple Ascending Dose (MAD) study of NM-0127 (Envelta) for Neuropathic pain
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2023
Price :
$35
*
At a glance
- Drugs Leucine enkephalin (Primary)
- Indications Cancer pain; Neuropathic pain; Post-traumatic stress disorders
- Focus Adverse reactions; First in man
- Sponsors Virpax Pharmaceuticals
- 15 Nov 2023 According to a Virpax Pharmaceuticals media release, company is expect to submit the IND by in mid-2024 and initiate first in human trials in 2024.
- 05 Apr 2023 According to a Virpax Pharmaceuticals media release, company is on track to file the IND by the second quarter of 2024.
- 10 Feb 2022 According to a Virpax Pharmaceuticals media release, the company remains focused on the next steps so that it may submit an IND and then initiate a Phase 1 study in humans upon any potential FDA acceptance.